Nexthera Capital as of Dec. 31, 2015
Portfolio Holdings for Nexthera Capital
Nexthera Capital holds 45 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pfizer (PFE) | 15.1 | $11M | 330k | 32.28 | |
| Bristol Myers Squibb (BMY) | 14.2 | $10M | 146k | 68.79 | |
| Celgene Corporation | 13.6 | $9.6M | 80k | 119.76 | |
| Merck & Co (MRK) | 7.8 | $5.5M | 104k | 52.82 | |
| Seattle Genetics | 5.7 | $4.0M | 90k | 44.88 | |
| Abbvie (ABBV) | 5.2 | $3.6M | 62k | 59.24 | |
| Concert Pharmaceuticals I equity | 4.9 | $3.5M | 183k | 18.97 | |
| Horizon Pharma | 4.4 | $3.1M | 144k | 21.67 | |
| Allergan | 4.1 | $2.9M | 9.2k | 312.50 | |
| Alder Biopharmaceuticals | 2.8 | $2.0M | 60k | 33.03 | |
| Neurocrine Biosciences (NBIX) | 2.2 | $1.5M | 27k | 56.56 | |
| Lion Biotechnologies | 1.7 | $1.2M | 152k | 7.72 | |
| Five Prime Therapeutics | 1.3 | $892k | 22k | 41.49 | |
| Neuroderm Ltd F | 1.2 | $818k | 48k | 17.04 | |
| Cti Biopharma | 1.1 | $807k | 656k | 1.23 | |
| Immune Design | 1.1 | $803k | 40k | 20.08 | |
| Aerie Pharmaceuticals | 1.0 | $688k | 28k | 24.36 | |
| Heron Therapeutics (HRTX) | 0.9 | $630k | 24k | 26.69 | |
| DURECT Corporation | 0.9 | $622k | 282k | 2.21 | |
| SciClone Pharmaceuticals | 0.8 | $598k | 65k | 9.20 | |
| Uniqure Nv (QURE) | 0.8 | $595k | 36k | 16.53 | |
| Advaxis | 0.8 | $556k | 55k | 10.06 | |
| Inotek Pharmaceuticals | 0.7 | $476k | 42k | 11.33 | |
| Oncothyreon | 0.6 | $444k | 200k | 2.22 | |
| Inovio Pharmaceuticals | 0.6 | $403k | 60k | 6.72 | |
| Vitae Pharmaceuticals | 0.5 | $375k | 21k | 18.10 | |
| Tobira Therapeutics Inc Common Stock Usd 0.0001 | 0.5 | $352k | 35k | 10.06 | |
| Gw Pharmaceuticals Plc ads | 0.5 | $347k | 5.0k | 69.40 | |
| Redhill Biopharma Ltd cmn | 0.4 | $309k | 24k | 12.88 | |
| Kamada Ord Ils1.00 (KMDA) | 0.4 | $302k | 72k | 4.19 | |
| Pronai Therapeutics | 0.4 | $301k | 20k | 15.05 | |
| Peregrine Pharmaceuticals | 0.4 | $287k | 245k | 1.17 | |
| Merrimack Pharmaceuticals In | 0.4 | $284k | 36k | 7.89 | |
| Scynexis | 0.3 | $246k | 40k | 6.20 | |
| Advanced Accelerat spon ads each rep 2 ord | 0.3 | $235k | 7.5k | 31.33 | |
| Neos Therapeutics | 0.3 | $215k | 15k | 14.33 | |
| Minerva Neurosciences | 0.3 | $207k | 34k | 6.07 | |
| Marinus Pharmaceuticals | 0.3 | $191k | 25k | 7.64 | |
| Vascular Biogenics | 0.2 | $175k | 33k | 5.25 | |
| Celator Pharmaceuticals | 0.2 | $158k | 90k | 1.76 | |
| Zynerba Pharmaceuticals | 0.2 | $151k | 15k | 10.07 | |
| Cerulean Pharma | 0.2 | $140k | 50k | 2.80 | |
| Fibrocell Science | 0.2 | $137k | 30k | 4.57 | |
| Tetrelogic Pharmaceuticals (TLOG) | 0.2 | $111k | 64k | 1.73 | |
| Genvec | 0.1 | $35k | 19k | 1.83 |
